Literature DB >> 17089032

Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease.

Thomas Wehler1, Felix Wolfert, Carl C Schimanski, Ines Gockel, Wolfgang Herr, Stefan Biesterfeld, Joachim K Seifert, Hassan Adwan, Martin R Berger, Theodor Junginger, Peter R Galle, Markus Moehler.   

Abstract

Certain chemokines have been proposed to distinctly contribute to tumor growth, dissemination and local immune escape. Expression of the chemokine receptor CXCR4 has been linked to tumor progression in diverse tumor entities. The aim of this study was to evaluate if the expression of CXCR4 influences progression of human pancreatic cancer. CXCR4 expression of pancreatic cancer was retrospectively assessed by immunohistochemistry in 103 patients with pancreatic cancer. Intensity of CXCR4 expression was correlated with both tumor and patient characteristics. Human pancreatic cancer revealed variable intensities of CXCR4 expression. Strong CXCR4 expression was significantly associated with advanced UICC stages (P=0.03) and revealed a trend for hematogenous metastasis (P=0.09) and progressed local tumor stages (P=0.15). In summary, strong expression of CXCR4 was significantly associated with advanced pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089032

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  29 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 3.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

Review 4.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 5.  Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.

Authors:  M Mimeault; S K Batra
Journal:  Gut       Date:  2008-10       Impact factor: 23.059

Review 6.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer.

Authors:  Jianbo Zhang; Chengxin Liu; Xinkai Mo; Huan Shi; Sheng Li
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

Review 9.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

10.  Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease.

Authors:  Thomas C Wehler; Claudine Graf; Stefan Biesterfeld; Walburgis Brenner; Jörg Schadt; Ines Gockel; Martin R Berger; Joachim W Thüroff; Peter R Galle; Markus Moehler; Carl C Schimanski
Journal:  J Oncol       Date:  2008-12-30       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.